Last updated: July 17, 2026
Boehringer Ingelheim Pharmaceuticals, Inc. sued Anobri Pharmaceuticals US, LLC in a Hatch-Waxman patent case filed in 2023 under case number 1:23-cv-00716. The docket shows an infringement dispute tied to FDA-linked generic entry under 21 U.S.C. §355(b)(2) and §355(j), with typical defenses focused on non-infringement and invalidity. The matter’s litigation posture and key claim/construction outcomes cannot be deterministically summarized here because the record details (asserted patents, Orange Book listings, infringement theories, and procedural milestones) are not included in the information provided.
What patents are asserted in Boehringer Ingelheim v. Anobri Pharmaceuticals US (1:23-cv-00716)?
Answer: Not specified in the provided inputs.
Which Orange Book patents did BI allege are infringed?
Answer: Not specified in the provided inputs.
Are the asserted patents composition, formulation, or method-of-use?
Answer: Not specified in the provided inputs.
What dosage forms and strengths are at issue?
Answer: Not specified in the provided inputs.
What is the procedural posture of 1:23-cv-00716 (filed date, motions, rulings, trial schedule)?
Answer: Not specified in the provided inputs.
What motions were decided (dismissal, summary judgment, preliminary injunction)?
Answer: Not specified in the provided inputs.
Has the court issued claim construction or Markman rulings?
Answer: Not specified in the provided inputs.
What is the current case status (active, stayed, settled, or terminated)?
Answer: Not specified in the provided inputs.
What defenses has Anobri raised in the Boehringer Ingelheim case?
Answer: Not specified in the provided inputs.
What non-infringement arguments are typical in this posture?
Answer: Not specified in the provided inputs.
What invalidity grounds are typical (anticipation, obviousness, §112)?
Answer: Not specified in the provided inputs.
Has Anobri raised a patent-exhaustion, prosecution-history-estoppel, or inequitable-conduct theory?
Answer: Not specified in the provided inputs.
Does the case involve a Paragraph IV certification, and when was it filed?
Answer: Not specified in the provided inputs.
What FDA application type is implicated (ANDA, 505(b)(2))?
Answer: Not specified in the provided inputs.
Which certification triggers the suit (Paragraph IV to which patent)?
Answer: Not specified in the provided inputs.
How strong is Boehringer Ingelheim’s patent estate in this dispute?
Answer: Not specified in the provided inputs.
Are there multiple patents per product or a single-family case?
Answer: Not specified in the provided inputs.
Are there known continuation, reissue, or enforcement-history signals?
Answer: Not specified in the provided inputs.
What generic entry risks does Anobri face if BI prevails?
Answer: Not specified in the provided inputs.
What is the practical impact on FDA approval timing?
Answer: Not specified in the provided inputs.
Can BI seek an injunction, or is the remedy limited by settlement?
Answer: Not specified in the provided inputs.
What litigation outcomes matter for investors and licensing planners?
Answer: Not specified in the provided inputs.
If the case settles, what terms are typically included?
Answer: Not specified in the provided inputs.
If the case proceeds, what outcomes control market entry?
Answer: Not specified in the provided inputs.
How does this case compare with other BI Hatch-Waxman disputes?
Answer: Not specified in the provided inputs.
Do prior BI cases show consistent claim construction trends or invalidity success rates?
Answer: Not specified in the provided inputs.
Key Takeaways
- 1:23-cv-00716 is a BI vs. Anobri Hatch-Waxman style patent infringement dispute filed in 2023.
- The provided inputs do not include asserted patent numbers, Orange Book listings, procedural milestones, or court orders, so a litigation-specific analysis of merits, timing, and entry risk cannot be produced from the information available.
FAQs
- What is the jurisdiction and venue for Boehringer Ingelheim v. Anobri Pharmaceuticals US (1:23-cv-00716)?
- What FDA product and NDA/ANDA numbers are linked to 1:23-cv-00716?
- Which patents are listed in the complaint and what claims does BI allege are infringed?
- Has the court issued any orders affecting claim construction, injunctions, or trial scheduling?
- What is the settlement or termination status for 1:23-cv-00716 and how does it affect FDA approval timing?
References
- Federal case docket: Boehringer Ingelheim Pharmaceuticals, Inc. v. Anobri Pharmaceuticals US, LLC, 1:23-cv-00716. (No further docket content provided.)
